-
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the effect of the use of benzodiazepines on prescription of opioids 4-7 years later in patients with noncancer pain.
A cohort of 7,991 men and 9,083 women aged 40, 45 and 60 years who reported no use of opioids in health surveys in 2000-2001 was linked to the nationwide Norwegian Prescription Database, and their prescriptions of opioids during 2004-2007 were analyzed. Moderate-high prescription frequency of opioids was defined as at least 12 prescriptions during the period January 2004-December 2007.
The unadjusted odds ratio for moderate-high prescription frequency of opioids for individuals who had previously used benzodiazepines was 7.7 (95% confidence interval 5.6-10.5) as compared with previous nonusers. After adjustment for musculoskeletal pain, alcohol, smoking habits, and socioeconomic variables, the odds ratio was lowered to 3.1 (2.1-4.6). The analysis of the effect of benzodiazepines and chronic pain individually and in combination suggest that use of benzodiazepines is an even stronger predictor of later opioid use than self-reported chronic pain.
Our study suggests that earlier use of benzodiazepines may predict repeated use of opioids. Before starting pain treatment with opioids, clinicians should take into consideration the possibility of substance abuse and mental health disorders. A central issue when prescribing opioids for chronic noncancer pain is to balance the risk of problematic use of these drugs with the benefits of pain relief.
Pain Medicine 06/2010; 11(6):805-14. · 2.35 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The use of anticholinergic antiparkinson drugs is almost exclusively confined to treating antipsychotic-induced extrapyramidal side effects (EPS). We investigated the prevalence of concomitant prescription of anticholinergics as a proxy for antipsychotic-induced EPS and compared variance in prevalence with differences in the assumed mechanisms of action of antipsychotics on central nervous system (CNS) transmitter systems (i.e., receptor drug-binding profiles). We paid special attention to potential differences between typical and atypical antipsychotics.
Data were drawn from the Norwegian Prescription Database on sales of antipsychotic and anticholinergic antiparkinson drugs to a total of 57,130 outpatients in 2004. We assessed concomitant dispensations of antipsychotic and anticholinergic drugs and correlated the prevalence of concomitantly prescribed anticholinergics to previously assessed receptor-binding profiles of antipsychotics.
The concurrent use of anticholinergics varied between 0.4% and 26.0% for patients using a single antipsychotic agent. The prevalence of anticholinergic comedication was more than twice as high in patients using two or more antipsychotic drugs. Four typical antipsychotics (fluphenazine, zuclopenthixol, haloperidol, and perphenazine) were associated with higher concomitant use of anticholinergics than the rest. For the remaining 14 antipsychotic agents, the difference between typical and atypical antipsychotics was neither pronounced nor systematic. A high degree of D2-receptor antagonism and a high 5-HT2A/D2-receptor-affinity ratio coincided with the use of anticholinergics.
The liability of antipsychotic drugs to cause EPS seemed to vary considerably and largely independently of the distinction between typical and atypical antipsychotics.
European Journal of Clinical Pharmacology 08/2009; 65(12):1229-35. · 2.85 Impact Factor
-
Southern medical journal 10/2008; 101(10):1074-5. · 0.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Drugs prescribed for the treatment of insomnia can be either benzodiazepine hypnotics or the newer z-hypnotics, zopiclone and zolpidem. This paper explores possible explanations for the choice made.
Data from the Norwegian Prescription Database covering the entire population was studied for incident users of hypnotics. Possible predictors were age, gender, previous psychotropic or analgesic drug use and prescriber speciality.
Of the 73,163 incident users of hypnotics, 3876 were prescribed benzodiazepine hypnotics in 2006. The strongest predictors for being prescribed benzodiazepines were previous use of anxiolytics [odds ratio (OR) 1.8, 95% confidence interval (CI) 1.7-2.0] and male gender (OR 1.5, 95% CI 1.4-1.6). Other significant predictors were antipsychotic or opioid drug use and the prescriber being a psychiatrist.
Z-hypnotics were commonly prescribed. Norwegian drug therapy recommendations also suggest a preference for z-hypnotics. The clear predominance of the shorter acting z-hypnotics may be due to the fact that only longer acting benzodiazepines are available in Norway. Reasons for prescribing benzodiazepines may be co-morbid psychiatric illness, such as anxiety, or a belief that benzodiazepine hypnotics are more effective than z-hypnotics.
European Journal of Clinical Pharmacology 10/2008; 65(3):295-301. · 2.85 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Carisoprodol is a drug frequently prescribed for lower back pain. Several case reports on the toxic potential have been published. Larger autopsy materials have supported the high toxicity of the drug, but have also shown that carisoprodol most often appears in mixed intoxications. The present study reports on contacts concerning possible intoxications with carisoprodol to the Norwegian Poisons Information Department. From 1992 to 2003, the number of contacts concerning carisoprodol rose heavily, also when adjusting for increasing total number of contacts. There was a relationship between the whole sales figure of carisoprodol and the number of contacts. Of the cases classified as "serious intoxications", carisoprodol was the second most frequent drug, only surpassed by acetaminophen (paracetamol). Despite the potential weaknesses of the present material, this study gave an additional indication of a high toxicity of carisoprodol.
Clinical Toxicology 05/2008; 46(4):307-9. · 2.22 Impact Factor
